Amsterdam / December 4, 2017 – Teva Pharmaceuticals Europe BV is pleased to announce the presentation of the 2017 Enrico Greppi Award by the Italian Society for the Study of Headaches (Società Italiana per lo Studio delle Cefalee) (SISC) at this year’s European Headache Federation (EHF) congress in Rome, Italy on Sunday Morning. The wining team – which included co-first authors, Dr Daniel Serrano & Professor Richard B. Lipton (pictured) – was awarded the 2017 Enrico Greppi Award for the best unpublished original paper dealing with clinical, epidemiological, genetic, pathophysiological or therapeutic aspects of headache. The award, which includes a prize of €10,000, will see the team’s winning paper published ex officio in The Journal of Headache and Pain.
The winning team presented research entitled, “Fluctuations in episodic and chronic migraine status over the course of one year: implications for diagnosis, treatment and clinical trial design.” Speaking at the awards ceremony in Rome, and accepting the Greppi Award on behalf of the team, Professor Richard B. Lipton (pictured) said, “We’re excited and honoured to receive the Enrico Greppi Award. On behalf of my colleagues, I’d like to thank the Greppi Awards selection committee for their recognition of our research in migraine. It’s this recognition that helps generate awareness and drives interest into ongoing advances in diagnosing, researching and treating migraine. And that’s exciting for our team.”
The Greppi Award is supported through an educational grant from Teva Neuroscience. Dr. Boukje de Vries, Associate Medical Director, Teva Neuroscience Europe, explains, “Even though migraine is a prevalent disease, it’s still a vastly underdiagnosed condition. So Teva is keen to continue its work with the neurology community to look for new and better ways to diagnose, research and treat migraine. We’re pleased to be able to support The Enrico Greppi Award through our educational grant, and look forward to continuing that support in 2018.”
The Italian Society for the Study of Headaches (Società Italiana per lo Studio delle Cefalee) (SISC) sponsors this international award in memory of Enrico Greppi (1899-1969). Greppi was a pioneer in the field of headache, and in 1954 in Florence he founded the first Headache Center in Europe. The winning team was chosen by an international selection committee, which evaluated numerous submissions. In commenting on the winning submission, Professor Francesco Pierelli, President of the SISC, explained, “This year’s winning paper, dealing with the stability of a diagnosis of episodic migraine or chronic migraine over time, confirmed substantial variation in headache day frequency in these patients. The results are of importance for headache classification and diagnosis, for the design and interpretation of epidemiologic and clinical studies, and also clinical management.”
Professor Paolo Martelletti, President of the European Headache Federation Council, added, “The Greppi Award was instituted in 1983, and the first lecture was held in the same year in Munich during the 1st Congress of the International Headache Society. The Award can boast the most eminent scientists in the headache field among its winners, Michael Moskowitz being the first recipient. Over the years, the Greppi lecture was held during the Congresses of the International Headache Society (IHS), then the European Pain Federation (EFIC) and now that of the European Headache Federation. The Award is given by an international committee that evaluates the numerous submissions in double blind mode. The winning manuscript obtains ex officio the publication in The Journal of Headache and Pain, EHF's official journal.
For more information on the Enrico Greppi Awards, or for queries regarding the 2018 Enrico Greppi Award submission requirements and deadlines, please click here or contact the Italian Society for the Study of Headaches (Società Italiana per lo Studio delle Cefalee) at email@example.com.
Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions.
With its European headquarters in Amsterdam, the Netherlands, Teva is also the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion (approximately €20.8 billion).
For more information, visit, http://www.tevaeurope.com/news